# Eloralintide Weight Loss Results: Phase 2 Data and What to Watch in Phase 3
> Note: PeptIQ is not a medical provider. Trial averages are not personal guarantees. Investigational status applies. Educational content only.
Your "retatrutide not working" article wins because searchers hit a frustration query. Eloralintide weight loss results is the complementary intent: people want the number, then they want to know if it is real.
Phase 2 Headline Results
In Lilly's Phase 2 study of once-weekly eloralintide in adults with obesity or overweight (without type 2 diabetes), all active arms beat placebo on percent weight change at 48 weeks.
Public efficacy-estimand figures (rounded for readability):
| Weekly regimen | Approx. mean weight change @ 48 weeks |
|---|---|
| 1 mg | ~−9% |
| 3 mg | ~−12% |
| 6 mg | ~−18% |
| 9 mg | ~−20% |
| 6→9 mg escalation | ~−20% |
| 3→6→9 mg escalation | ~−16% |
| Placebo | ~0% |
Lilly summarized the range as about 9.5% to 20.1% mean reduction across treatment arms vs 0.4% placebo (efficacy estimand), presented at ObesityWeek 2025 and published in The Lancet.
That is a serious monotherapy signal for an amylin agonist.
How to Interpret "Up to 20%" Like an Adult
Trial means are not Instagram transformations.
- Efficacy estimand answers: if people stay on assigned treatment, what happens?
- Treatment-regimen / treatment-policy estimands answer: what happens including discontinuations and real-world messiness?
- Phase 3 will emphasize the estimands regulators care about
Also: ~20% at 9 mg does not mean every participant lost 20%. Distributions matter — responders, partial responders, and discontinuations.
How These Results Sit vs Other 2026 Headliners
| Program | Rough public weight-loss anchor | Pathway |
|---|---|---|
| Eloralintide Phase 2 | ~9–20% @ 48 weeks | Selective amylin |
| CagriSema REDEFINE 1 | ~20%+ combo @ 68 weeks | Amylin + GLP-1 |
| Survodutide SYNCHRONIZE-1 | ~12–13% treatment-regimen @ 76 weeks (higher on efficacy estimand) | Glucagon + GLP-1 |
| Orforglipron ATTAIN-1 | up to ~12% efficacy-style @ 72 weeks (oral) | Oral GLP-1 |
| Retatrutide TRIUMPH program | among the highest injectable multi-agonist signals | GLP-1 + GIP + glucagon |
Different durations, populations, and estimands — use as orientation, not a fantasy league ranking.
"It's Not Working" Troubleshooting (Any Amylin / Incretin Protocol)
Even with strong trial averages, individuals stall. The same checklist that performs for retatrutide applies:
1. Measurement problem, not drug problem
Waist, photos, and 7-day average weight beat a single morning scale spike.
2. Dose still in adaptation zone
Low fixed doses produced smaller mean loss in Phase 2. If someone is early in titration, "no miracle week 2" is normal.
